首页
小分子和化合物库
按“信号通路”分类
免疫学/炎症
CD20
Ocrelizumab (anti-CD20), CD20（跨膜 4-结构域；A 亚家族；成员 1）抗体

Ocrelizumab (anti-CD20), CD20（跨膜 4-结构域；A 亚家族；成员 1）抗体

级别和纯度:

≥95%(SDS-PAGE&SEC-HPLC)
见COA

应用:

Animal Model
ELISA
Flow Cytometry
Functional Assay

宿主种属: 人(Human)
种属反应性: 人(Human), 食蟹猴(Cynomolgus monkey)
亚型: Human IgG1
偶联: Unconjugated

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab175614-100μg	100μg	现货
Ab175614-1mg	1mg	现货
Ab175614-5mg	5mg	现货
Ab175614-10mg	10mg	期货

查看相关系列

点击查看靶蛋白信息: MS4A1

Accession#:P11836 (47) CD20 (48) CD20 (membrane-spanning 4-domains，subfamily A，member 1) Antibody (3) Gene ID:931 (47) MS4A1 (48)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Ocrelizumab (anti-CD20), CD20（跨膜 4-结构域；A 亚家族；成员 1）抗体
别名	奥美珠单抗 \| 奥瑞珠单抗(抗 CD20)
英文别名	APY antibody \| ATOPY antibody \| B lymphocyte antigen CD20 antibody \| B Lymphocyte Cell Surface Antigen B1 antibody \| B-lymphocyte antigen CD20 antibody \| B-lymphocyte cell-surface antigen B1 antibody \| B-lymphocyte surface antigen B1 antibody \| B1 antibod
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	MS4A1
种属反应性	人(Human),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated
作用类型	结合剂
作用机制	CD20（跨膜 4-结构域；A 亚家族；成员 1）抗体

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	145.82 kDa
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0.
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	637334-45-3
分子类型	抗体

关联靶点（人）

MS4A1 Tclin B淋巴细胞抗原CD20(B-lymphocyte antigen CD20) (0 活性数据)

点击查看靶蛋白信息： MS4A1

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

Flow Cytometry: Ocrelizumab (anti-CD20) (Ab175614)

Ocrelizumab (anti-CD20) (Ab175614) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD20 (red) with Ocrelizumab (anti-CD20) (Ab175614). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

SEC: Ocrelizumab (anti-CD20) (Ab175614)

Ocrelizumab (anti-CD20) (Ab175614) - SEC
The purity of Ocrelizumab (anti-CD20) (Ab175614) is more than 95% verified by HPLC.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到6个结果

批号(Lot Number)	证书类型	货号
ZJ24F1113275	分析证书	Ab175614
ZJ24F1113274	分析证书	Ab175614
ZJ24F1113273	分析证书	Ab175614
ZJ24F0102656	分析证书	Ab175614
ZJ24F0102655	分析证书	Ab175614
ZJ24F0102654	分析证书	Ab175614

可替换产品

引用文献

1. Vugmeyster Y, Beyer J, Howell K, Combs D, Fielder P, Yang J, Qureshi F, Sandlund B, Kawaguchi L, Dummer W et al.. (2005) Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis.. J Immunother, 28 (3): (212-9). [PMID:15838377]
2. Hutas G. (2008) Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.. Curr Opin Investig Drugs, 9 (11): (1206-15). [PMID:18951300]
3. Kausar F, Mustafa K, Sweis G, Sawaqed R, Alawneh K, Salloum R, Badaracco M, Niewold TB, Sweiss NJ. (2009) Ocrelizumab: a step forward in the evolution of B-cell therapy.. Expert Opin Biol Ther, 9 (7): (889-95). [PMID:19463076]
4. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B et al.. (2017) Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.. N Engl J Med, 376 (3): (209-220). [PMID:28002688]
5. Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, Baranzini SE, Leppert D, von Büdingen HC. (2014) Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.. J Immunol, 193 (2): (580-586). [PMID:24928997]
6. Gingele S, Jacobus TL, Konen FF, Hümmert MW, Sühs KW, Schwenkenbecher P, Ahlbrecht J, Möhn N, Müschen LH, Bönig L et al.. (2018) Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.. Cells, 8 (1): [PMID:30597851]
7. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E et al.. (2010) CD20 deficiency in humans results in impaired T cell-independent antibody responses.. J Clin Invest, 120 (1): (214-22). [PMID:20038800]
8. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. (2004) Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.. Clin Cancer Res, 10 (8): (2868-78). [PMID:15102696]
9. Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, Davi F, Debré P, Prost JF, Teillaud JL et al.. (2011) Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.. Leukemia, 25 (1): (101-9). [PMID:20975664]
10. Li B, Xu L, Pi C, Yin Y, Xie K, Tao F, Li R, Gu H, Fang J. (2017) CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.. Oncoimmunology, 7 (1): (e1380142). [PMID:29296544]
11. Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E et al.. (2015) Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.. Sci Transl Med, 7 (287): (287ra70). [PMID:25972002]
12. Tedder, T F TF, Streuli, M M, Schlossman, S F SF and Saito, H H.. (1988) Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2448768]
13. Einfeld, D A DA, Brown, J P JP, Valentine, M A MA, Clark, E A EA and Ledbetter, J A JA.. (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.. The EMBO journal, [PMID:2456210]
14. Tedder, T F TF, Klejman, G G, Schlossman, S F SF and Saito, H H.. (1989) Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1).. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:2466899]
15. Stamenkovic, I I and Seed, B B.. (1988) Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein.. The Journal of experimental medicine, (1): [PMID:3260267]
16. Tedder, T F TF, Boyd, A W AW, Freedman, A S AS, Nadler, L M LM and Schlossman, S F SF.. (1985) The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.. Journal of immunology (Baltimore, Md. : 1950), [PMID:3925015]
17. Bubien, J K JK, Zhou, L J LJ, Bell, P D PD, Frizzell, R A RA and Tedder, T F TF.. (1993) Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.. The Journal of cell biology, [PMID:7684739]
18. and Goldenberg, D M DM.. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy.. Critical reviews in oncology/hematology, [PMID:11418316]
19. and Dillman, R O RO.. Monoclonal antibody therapy for lymphoma: an update.. Cancer practice, [PMID:11879282]
20. (2003) Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, [PMID:12899647]
21. Li, Haidong H, Ayer, Linda M LM, Lytton, Jonathan J and Deans, Julie P JP.. (2003) Store-operated cation entry mediated by CD20 in membrane rafts.. The Journal of biological chemistry, (24): [PMID:12920111]
22. Du, Jiamu J and 8 more authors.. (2008) Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide.. Molecular immunology, [PMID:18346788]
23. Dörner, Thomas T and Burmester, Gerd R GR.. (2008) New approaches of B-cell-directed therapy: beyond rituximab.. Current opinion in rheumatology, [PMID:18388516]
24. Polyak, Maria J MJ, Li, Haidong H, Shariat, Neda N and Deans, Julie P JP.. (2008) CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins.. The Journal of biological chemistry, (4): [PMID:18474602]
25. Niederfellner, Gerhard G and 16 more authors.. (2011) Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.. Blood, (14): [PMID:21444918]
26. Ivaldi, Corinne C and 6 more authors.. (2012) Proteomic analysis of S-acylated proteins in human B cells reveals palmitoylation of the immune regulators CD20 and CD23.. PloS one, [PMID:22615937]
27. Phuah, Jiayao J and 10 more authors.. (2016) Effects of B Cell Depletion on Early Mycobacterium tuberculosis Infection in Cynomolgus Macaques.. Infection and immunity, [PMID:26883591]
28. Hayashi, Kazumi and 6 more authors.. (2016) Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.. Cancer science, [PMID:26920337]
29. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ.. (2002) TTD: Therapeutic Target Database.. Nucleic acids research, (1): [PMID:11752352]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Ocrelizumab (anti-CD20), CD20（跨膜 4-结构域；A 亚家族；成员 1）抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器